Table 4.

Sensitivity analysis for 1-, 2-, 3-, and 5-year OS rate, LRR, and DMR (CCRT vs. CCRT-CCT group).

Items	Study omitted	Estimate	95% CI
One-year OS rate	Wu et al. (15)	0.588	0.467	0.741
	Chen et al. (16)	0.667	0.538	0.826
	Chen et al. (17)	0.625	0.501	0.780
	Chen et al. (18)	0.651	0.528	0.802
	Koh et al. (19)	0.649	0.522	0.805
	Zhang et al. (20)	0.687	0.551	0.857
	Combined	0.644	0.528	0.786
Two-year OS rate	Wu et al. (15)	0.872	0.745	1.020
	Chen et al. (16)	0.888	0.765	1.030
	Chen et al. (17)	0.896	0.770	1.042
	Koh et al. (19)	0.894	0.777	1.028
	Combined	0.888	0.779	1.011
Three-year OS rate	Wu et al. (15)	0.907	0.825	0.998
	Chen et al. (16)	0.873	0.793	0.961
	Chen et al. (17)	0.915	0.831	1.007
	Chen et al. (18)	0.923	0.843	1.009
	Koh et al. (19)	0.918	0.840	1.003
	Zhang et al. (20)	0.941	0.858	1.032
	Combined	0.914	0.840	0.995
Five-year OS rate	Chen et al. (16)	0.902	0.810	1.004
	Chen et al. (17)	0.971	0.893	1.056
	Chen et al. (18)	0.994	0.912	1.078
	Zhang et al. (20)	1.017	0.935	1.106
	Combined	0.977	0.906	1.054
LRR	Wu et al. (15)	0.965	0.717	1.299
	Chen et al. (16)	0.660	0.424	1.028
	Chen et al. (17)	0.965	0.712	1.306
	Combined	0.899	0.686	1.179
DMR	Wu et al. (15)	1.211	0.782	1.874
	Chen et al. (16)	1.799	1.134	2.855
	Chen et al. (17)	1.761	1.145	2.709
	Combined	1.562	1.090	2.240

CCT, consolidation chemotherapy; CCRT, concurrent chemoradiotherapy; DMR, distant metastasis rate; LRR, local recurrence rate; OS, overall survival.